会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 5. 发明授权
    • Trimethyl lock based tetrapartate prodrugs
    • 基于三甲基锁的四聚物前药
    • US06624142B2
    • 2003-09-23
    • US09852335
    • 2001-05-09
    • Richard B. GreenwaldHong Zhao
    • Richard B. GreenwaldHong Zhao
    • A61K31222
    • C07C237/22A61K47/60C07B2200/11C07C271/16C07C271/22C07C271/48
    • The invention is directed primarily to compounds of Formula I: wherein: R1 is a polymeric residue; L1 is a bifunctional linking group; Y1 and Y2 are independently O, S or NR7; R2-7 are independently selected from the group consisting of hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls, substituted C1-6 heteroalkyls, C1-6 alkoxy, phenoxy and C1-6 heteroalkoxy; D is a moiety that is a leaving group or a residue of a compound to be delivered into a cell; Z is selected from the group consisting of: a moiety that is actively transported into a target cell, a hydrophobic moiety, and combinations thereof; Ar is a moiety which when included in Formula (I) forms a multi-substituted aromatic hydrocarbon or a multi-substituted heterocyclic group; and (y) is a positive integer greater than or equal to 1. Methods of making and using the same are also disclosed.
    • 本发明主要针对式I化合物:其中:R1是无规残基; L1是双官能连接基团; Y 1和Y 2独立地是O,S或NR 7; R 2-7独立地选自氢,C1 C6烷基,C3-12支链烷基,C3-8环烷基,C1-6取代烷基,C3-8取代环烷基,芳基,取代芳基,芳烷基,C1-6杂烷基,取代C1-6杂烷基,C1-6烷氧基, 苯氧基和C 1-6杂烷氧基; D是作为离开基团或待递送至细胞中的化合物的残基的部分; Z选自:主动转运入靶细胞的部分, 疏水部分及其组合; Ar是当式(I)中包含时形成多取代芳族烃或多取代杂环基的部分; 和(y)是大于或等于1的正整数。还公开了制造和使用它们的方法。
    • 6. 发明授权
    • High molecular weight polymer-based prodrugs
    • 高分子量聚合物基前药
    • US5965566A
    • 1999-10-12
    • US914927
    • 1997-08-20
    • Richard B. GreenwaldAnnapurna PendriHong Zhao
    • Richard B. GreenwaldAnnapurna PendriHong Zhao
    • A61K31/335A61K47/48C07D305/14C07D491/22C08G65/329A61K31/44
    • A61K47/48215A61K31/335C07D305/14C08G65/329
    • The present invention is directed compositions of the formula: ##STR1## wherein: D is a residue of biologically active moiety;X is an electron withdrawing group;Y and Y' are independently O or S;(n) is zero (0) or a positive integer, preferably from 1 to about 12;wherein: R.sub.1 and R.sub.2 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls and substituted C.sub.1-6 alkyls;wherein: R.sub.3 is a substantially non-antigenic polymer, C.sub.1-12 straight or branched alkyl or substituted allyl, C.sub.5-8 cycloalkyl or substituted cycloalkyl, carboxyalkyl, carboalkoxy alkyl, dialkylaminoalkyl, phenylalkyl, phenylaryl or ##STR2## wherein: R.sub.4 and R.sub.5 are independently selected from the group consisting of H, C.sub.1-6 alkyls, aryls, substituted aryls, aralkyls, heteroalkyls, substituted heteroalkyls, and substituted C.sub.1-6 alkyls or jointly form a cyclic C.sub.5 -C.sub.7 ring. In preferred embodiments, the prodrugs contain a polyethylene glycol having a molecular weight of at least about 20,000.
    • 本发明涉及下式的组合物:其中:D是生物活性部分的残基; X是吸电子基团; Y和Y'独立地为O或S; (n)为零(0)或正整数,优选1至约12; 其中:R 1和R 2独立地选自H,C 1-6烷基,芳基,取代的芳基,芳烷基,杂烷基,取代的杂烷基和取代的C 1-6烷基; 其中:R3是基本上非抗原性的聚合物,C1-12直链或支链烷基或取代的烯丙基,C5-8环烷基或取代的环烷基,羧基烷基,烷氧基烷基,二烷基氨基烷基,苯基烷基,苯基芳基或其中:R4和R5独立地选自 由H,C 1-6烷基,芳基,取代的芳基,芳烷基,杂烷基,取代的杂烷基和取代的C 1-6烷基组成的基团或共同形成环状C 5 -C 7环。 在优选的实施方案中,前药包含分子量为至少约20,000的聚乙二醇。
    • 8. 发明授权
    • Biodegradable high molecular weight polymeric linkers and their conjugates
    • 可生物降解的高分子量聚合物接头及其共轭物
    • US06824766B2
    • 2004-11-30
    • US09888072
    • 2001-06-22
    • Richard B. GreenwaldHong Zhao
    • Richard B. GreenwaldHong Zhao
    • A61K31785
    • A61K47/60
    • The present invention includes polymeric transport systems corresponding to the formula: wherein: R31 is a linear or branched polymer residue; Y10 and Y11 are independently O, S, or NR40; X2 is O, S or NR41; R32-35, R37-41, R50 and R51 are independently selected among hydrogen, C1-6 alkyls, C3-12 branched alkyls, C3-8 cycloalkyls, C1-6 substituted alkyls, C3-8 substituted cycloalkyls, aryls, substituted aryls, aralkyls, C1-6 heteroalkyls and substituted C1-6 heteroalkyls; a, b and e are each independently selected positive integers; L is an amino acid residue or a bifunctional linker; X3 is wherein Y12 and Y13 are independently O, S, or NR41; Z is a bond, a moiety that is actively transported into a target cell, a hydrophobic moiety or combinations thereof; D1 and D2 are OH, a residue of a hydroxyl, a residue of an amine-containing moiety or a leaving group; and y1 and y2 are independently selected positive integers.
    • 本发明包括对应于下式的聚合物输送系统:其中:R 31是直链或支链聚合物残基; Y10和Y11独立地为O,S或NR40; X2是O,S或NR41; R32-35,R37-41,R50和R51独立地选自氢,C1-6烷基,C3-12支链烷基,C3-8环烷基,C1-6取代的烷基,C3-8取代的环烷基,芳基,取代的芳基, 芳烷基,C 1-6杂烷基和取代的C 1-6杂烷基; a,b和e各自独立选择正整数; L是氨基酸残基或双功能连接体; X3中Y12和Y13独立地为O,S或NR41; Z是一个键,一个主要被运送到靶细胞中的部分,一个疏水部分或它们的组合; D1和D2是OH,羟基的残基,含胺部分的残基或离去基团; y1和y2是独立选择的正整数。